FATRO’s Vaccine Expansion: New Technologies, Startups, and a Quality-First Strategy

27/01/2026

Recorded in Turkiye at the 3rd Fatro & Gunesli Regional Animal Health Symposium, this interview explores how FATRO is broadening its animal health portfolio by moving deeper into the vaccine segment—alongside its established focus on metabolism, reproduction, mastitis, antibacterial products, and non-steroidal anti-inflammatory drugs.

Dr. Roberto Farina explains that FATRO already holds a large internal databank of antigens, positioning the company to develop “many” new vaccines in the coming years. The next challenge, he says, is to improve vaccine security and efficacy, which the company aims to achieve through newer technologies and biotechnologies—such as bioengineering—while also collaborating with a growing number of startups and universities to shape what he calls the “vaccines of the future.”

The conversation also returns to metabolic management, an area Farina describes as complex but central—particularly for dairy cows, and increasingly across other species. He notes FATRO’s long-standing role in treating metabolic disorders and points to Metabolase and Hepagent as two of the company’s key metabolic products globally. Because metabolic disorders involve many interconnected systems, he adds, FATRO is also looking to advanced tools like artificial intelligence to better understand and manage these complex biological processes.

Closing the interview, Farina highlights what he calls FATRO’s driving force: uncompromising production quality. While some products may be priced higher than competitors, he argues that guaranteed quality, reliability, stability, and veterinarian trust are the strategic pillars behind the company’s approach—and remain central to its mission.

Watch the full exclusive interview on the official The Animal Economics YouTube channel.